265 related articles for article (PubMed ID: 34769235)
1. Hydroxylation of the Acetyltransferase NAA10 Trp38 Is Not an Enzyme-Switch in Human Cells.
Ree R; Krogstad K; McTiernan N; Jakobsson ME; Arnesen T
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769235
[TBL] [Abstract][Full Text] [Related]
2. FIH permits NAA10 to catalyze the oxygen-dependent lysyl-acetylation of HIF-1α.
Kang J; Chun YS; Huh J; Park JW
Redox Biol; 2018 Oct; 19():364-374. PubMed ID: 30237125
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Lysine Acetyltransferase Activity of Recombinant Human ARD1/NAA10.
Vo TTL; Park JH; Lee EJ; Nguyen YTK; Han BW; Nguyen HTT; Mun KC; Ha E; Kwon TK; Kim KW; Jeong CH; Seo JH
Molecules; 2020 Jan; 25(3):. PubMed ID: 32013195
[TBL] [Abstract][Full Text] [Related]
4. N-α-acetyltransferase 10 (NAA10) in development: the role of NAA10.
Lee MN; Kweon HY; Oh GT
Exp Mol Med; 2018 Jul; 50(7):1-11. PubMed ID: 30054454
[TBL] [Abstract][Full Text] [Related]
5. The N-terminal Acetyltransferase Naa10/ARD1 Does Not Acetylate Lysine Residues.
Magin RS; March ZM; Marmorstein R
J Biol Chem; 2016 Mar; 291(10):5270-7. PubMed ID: 26755727
[TBL] [Abstract][Full Text] [Related]
6.
McTiernan N; Darbakk C; Ree R; Arnesen T
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255974
[TBL] [Abstract][Full Text] [Related]
7.
Kweon HY; Lee MN; Dorfel M; Seo S; Gottlieb L; PaPazyan T; McTiernan N; Ree R; Bolton D; Garcia A; Flory M; Crain J; Sebold A; Lyons S; Ismail A; Marchi E; Sonn SK; Jeong SJ; Jeon S; Ju S; Conway SJ; Kim T; Kim HS; Lee C; Roh TY; Arnesen T; Marmorstein R; Oh GT; Lyon GJ
Elife; 2021 Aug; 10():. PubMed ID: 34355692
[TBL] [Abstract][Full Text] [Related]
8. A novel NAA10 p.(R83H) variant with impaired acetyltransferase activity identified in two boys with ID and microcephaly.
Ree R; Geithus AS; Tørring PM; Sørensen KP; Damkjær M; ; Lynch SA; Arnesen T
BMC Med Genet; 2019 Jun; 20(1):101. PubMed ID: 31174490
[TBL] [Abstract][Full Text] [Related]
9. The N-end rule pathway enzyme Naa10 supports epiblast specification in mouse embryonic stem cells by modulating FGF/MAPK.
Takekoshi D; Tokuzawa Y; Sakanaka M; Kato H
In Vitro Cell Dev Biol Anim; 2019 May; 55(5):355-367. PubMed ID: 30993557
[TBL] [Abstract][Full Text] [Related]
10. Versatility of ARD1/NAA10-mediated protein lysine acetylation.
Vo TTL; Jeong CH; Lee S; Kim KW; Ha E; Seo JH
Exp Mol Med; 2018 Jul; 50(7):1-13. PubMed ID: 30054464
[TBL] [Abstract][Full Text] [Related]
11. A novel NAA10 variant with impaired acetyltransferase activity causes developmental delay, intellectual disability, and hypertrophic cardiomyopathy.
Støve SI; Blenski M; Stray-Pedersen A; Wierenga KJ; Jhangiani SN; Akdemir ZC; Crawford D; McTiernan N; Myklebust LM; Purcarin G; McNall-Knapp R; Wadley A; Belmont JW; Kim JJ; Lupski JR; Arnesen T
Eur J Hum Genet; 2018 Sep; 26(9):1294-1305. PubMed ID: 29748569
[TBL] [Abstract][Full Text] [Related]
12. A Saccharomyces cerevisiae model reveals in vivo functional impairment of the Ogden syndrome N-terminal acetyltransferase NAA10 Ser37Pro mutant.
Van Damme P; Støve SI; Glomnes N; Gevaert K; Arnesen T
Mol Cell Proteomics; 2014 Aug; 13(8):2031-41. PubMed ID: 24408909
[TBL] [Abstract][Full Text] [Related]
13. The biological functions of Naa10 - From amino-terminal acetylation to human disease.
Dörfel MJ; Lyon GJ
Gene; 2015 Aug; 567(2):103-31. PubMed ID: 25987439
[TBL] [Abstract][Full Text] [Related]
14. Investigating the functionality of a ribosome-binding mutant of NAA15 using Saccharomyces cerevisiae.
Varland S; Arnesen T
BMC Res Notes; 2018 Jun; 11(1):404. PubMed ID: 29929531
[TBL] [Abstract][Full Text] [Related]
15. Biochemical analysis of novel NAA10 variants suggests distinct pathogenic mechanisms involving impaired protein N-terminal acetylation.
McTiernan N; Tranebjærg L; Bjørheim AS; Hogue JS; Wilson WG; Schmidt B; Boerrigter MM; Nybo ML; Smeland MF; Tümer Z; Arnesen T
Hum Genet; 2022 Aug; 141(8):1355-1369. PubMed ID: 35039925
[TBL] [Abstract][Full Text] [Related]
16. Evaluating possible maternal effect lethality and genetic background effects in Naa10 knockout mice.
Lyon GJ; Longo J; Garcia A; Inusa F; Marchi E; Shi D; Dörfel M; Arnesen T; Aldabe R; Lyons S; Nashat MA; Bolton D
PLoS One; 2024; 19(5):e0301328. PubMed ID: 38713657
[TBL] [Abstract][Full Text] [Related]
17. NAA10-related syndrome.
Wu Y; Lyon GJ
Exp Mol Med; 2018 Jul; 50(7):1-10. PubMed ID: 30054457
[TBL] [Abstract][Full Text] [Related]
18. NAA10 p.(N101K) disrupts N-terminal acetyltransferase complex NatA and is associated with developmental delay and hemihypertrophy.
McTiernan N; Gill H; Prada CE; Pachajoa H; Lores J; ; Arnesen T
Eur J Hum Genet; 2021 Feb; 29(2):280-288. PubMed ID: 32973342
[TBL] [Abstract][Full Text] [Related]
19. Severe syndromic ID and skewed X-inactivation in a girl with NAA10 dysfunction and a novel heterozygous de novo NAA10 p.(His16Pro) variant - a case report.
Bader I; McTiernan N; Darbakk C; Boltshauser E; Ree R; Ebner S; Mayr JA; Arnesen T
BMC Med Genet; 2020 Jul; 21(1):153. PubMed ID: 32698785
[TBL] [Abstract][Full Text] [Related]
20. NAA10 as a New Prognostic Marker for Cancer Progression.
Kim SM; Ha E; Kim J; Cho C; Shin SJ; Seo JH
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
